Hikma gets FDA approval for generic narcolepsy treatment
Hikma Pharmaceuticals’ US subsidiary Roxane Laboratories has received approval from the US Food and Drug Administration for its sodium oxybate oral solution for the treatment of cataplexy – sudden loss of muscle strength – and excessive daytime sleepiness in patients with narcolepsy.
FTSE 100
8,438.65
17:10 16/05/24
n/a
n/a
FTSE 350
4,642.54
17:15 16/05/24
n/a
n/a
FTSE All-Share
4,594.70
16:50 16/05/24
n/a
n/a
Hikma Pharmaceuticals
1,983.00p
16:49 16/05/24
-2.22%
-45.00p
Pharmaceuticals & Biotechnology
23,433.99
17:15 16/05/24
-0.46%
-109.29
The sodium oxybate oral solution is the generic equivalent to Jazz Pharmaceuticals’ Xyrem, for which the company reported net sales of about $955m in 2015.
Roxane is currently involved in patent litigation concerning this product in the US District Court for the District of New Jersey.
At 1010 GMT, Hikma shares were up 1.9% to 1,950p.